Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by muscle degeneration and weakness. Duchenne muscular dystrophy (DMD) cause due to lack of protein known as dystrophin which causes muscles deterioration and break down, leads to difficulty in walking and general mobility.

DMD is a one of the most progressive childhood neuromuscular disorders. It affects mostly boys, but occasionally girls are affected.

DMD can be caused due to cardiac, neuromuscular, and orthopedic disorders.

Increasing research and development, introduction of novel disease therapies, rising demand for effective therapies among patients, and increasing disease prevalence are projected to fuel the growth of the global Duchenne muscular dystrophy market. According to the Centers for Disease Control and Prevention, in 2016, prevalence of Duchenne and Becker muscular dystrophy (DBMD) was 1 in every 7,250 males aged 5 to 24 years.

Rising prevalence of chronic diseases such as cardiovascular, neurovascular, and arthritis, and increasing health care insurance coverage are the other factors likely to accelerate the growth of the global Duchenne muscular dystrophy market. According to the World Health Organization, cardiovascular diseases accounted for 17.7 million deaths in 2015, representing 31% of all global deaths.

However, stricter regulation for product approvals and high product cost are likely to restrain the Duchenne muscular dystrophy market.

The Duchenne muscular dystrophy (DMD) market has been segmented based on treatment type, diagnosis, end-user, and region. In terms of treatment type, the market has been classified into drug therapy and novel therapy.

The drug therapy segment has been sub-segmented into corticosteroids and others. The novel therapy segment has been categorized into gene therapy, stem cell therapy, utrophin, and others.

In terms of diagnosis, the Duchenne muscular dystrophy market has been classified into blood tests, gene tests, and muscle biopsy. Based on end-user, the market has been classified into hospitals, specialty clinics, and ambulatory surgery centers.

View Report-

http://www.transparencymarketresearch.com/duchenne-muscular-dystrophy-market.html

Geographically, the Duchenne muscular dystrophy market has been segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America dominates the global Duchenne muscular dystrophy market due to new product innovation, high health care expenditure, and government awareness programs.

The United Parent Projects Muscular Dystrophy initiated World Duchenne Awareness Day. The aim of Duchenne Awareness Day is to raise awareness about Duchenne muscular dystrophy across the globe and September 7 has been declared as Duchenne Awareness Day.

Europe is the second largest market for Duchenne muscular dystrophy. The market in Asia Pacific is expected to grow at higher rate due to rapid rise in population, growing prevalence of chronic diseases, increasing health care coverage, and rising investment in research and development.

Emerging regions such as Latin America and Middle East & Africa will create a large opportunity in the global Duchenne muscular dystrophy market due to growing awareness among people, increasing public and private health care insurance coverage, etc.

Major players operating in the global Duchenne muscular dystrophy market include Pfizer, Inc., Eli Lilly and Company, Nobelpharma Co., Ltd., Sarepta Therapeutics, Inc., Tivorsan Pharmaceuticals, Acceleron Pharma, Inc., BioMarin Pharmaceutical, Inc., Asklepios Kliniken GmbH, FibroGen, Inc., and Santhera Pharmaceuticals Holding.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size.

The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The regional analysis covers:

North America (U.S. and Canada)

Latin America (Mexico, Brazil, Peru, Chile, and others)

Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)

Eastern Europe (Poland and Russia)

Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)

Middle East and Africa (GCC, Southern Africa, and North Africa)

Request a brochure of this report to know what opportunities will emerge in the rapidly evolving Duchenne Muscular Dystrophy (DMD) Market during 2017- 2025

http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=28145

View original post here:
Understanding the muscle behind global duchenne muscular dystrophy market - WhaTech